A study of aspects on gender and prognosis in synchronous colorectal cancer [0.03%]
关于同步性结直肠癌的性别与预后的研究分析
Kristoffer Derwinger,Bengt Gustavsson
Kristoffer Derwinger
Aim: To assess differences in demography, pathology and prognosis with tumor multiplicity in colorectal cancer. Method: A retrospective...
Transgenic and knockout mice models to reveal the functions of tumor suppressor genes [0.03%]
转基因和基因敲除小鼠模型揭示肿瘤抑制基因功能
Pankaj Taneja,Sinan Zhu,Dejan Maglic et al.
Pankaj Taneja et al.
Cancer is caused by multiple genetic alterations leading to uncontrolled cell proliferation through multiple pathways. Malignant cells arise from a variety of genetic factors, such as mutations in tumor suppressor genes (TSGs) that are invo...
Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer [0.03%]
复发性小细胞肺癌的当前和新兴药物疗法
Binu S Nair,Vipul Bhanderi,Syed H Jafri
Binu S Nair
Small cell lung cancer (SCLC) is a very aggressive cancer with poor outcome if left untreated, but it is also one of the most chemotherapy responsive cancers. Overall it has a very poor prognosis especially if it is chemotherapy resistant t...
Hari Deshpande,Sanziana Roman,Jaykumar Thumar et al.
Hari Deshpande et al.
Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal...
Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide [0.03%]
阿片类药物引起的便秘：溴甲基纳曲酮的安全性和有效性
S Bader,K Jaroslawski,H E Blum et al.
S Bader et al.
Constipation, one of the major side effects of opiates used in palliative care, can impair patients' quality of life to a point where it prevents sufficient pain control. Methylnaltrexone is a novel μ-receptor antagonist, which does not pa...
Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML [0.03%]
二线药物作为新诊断的慢性期CML患者的一线治疗药物的发展趋势分析
Marie P Shieh,Masato Mitsuhashi,Michael Lilly
Marie P Shieh
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second g...
Neonatal systemic juvenile xanthogranuloma with an ominous presentation and successful treatment [0.03%]
凶险起病的新生儿全身性系统性幼年黄色肉芽肿病例及治疗体会
Rong Fan,Jihong Sun
Rong Fan
This case report originated from a case of neonatal multisystemic juvenile xanthogranuloma (JXG). The patient presented with blue muffin rush, cervical mass, bone destruction, lung nodule, hepatosplenomegaly, and coagulopathy and was succes...
Amanda M Sherrod,Adam Brufsky,Shannon Puhalla
Amanda M Sherrod
Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although its major dose-limiting side effect is myelosuppression, many pulmonary toxicities have been described with its use. Severe pulmonary toxic...
Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer [0.03%]
长春地辛治疗非小细胞肺癌的疗效及安全性评估
Bryan A Faller,Trailokya N Pandit
Bryan A Faller
Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with ...
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma [0.03%]
苯达莫司汀治疗惰性非霍奇金淋巴瘤安全性和有效性的系统综述和 meta 分析
Nishant Tageja
Nishant Tageja
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent...